StockWatch: Biogen's Q4 Results Disappoint Analysts genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
BRISBANE, Calif., Feb. 02, 2024 Vera Therapeutics, Inc. , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with.
BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients
BRISBANE, Calif., Dec. 27, 2023 Vera Therapeutics, Inc. , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with.
AUR200, a potent recombinant fusion protein, has a clinically validated MOA with a high affinity for targeting both BAFF and APRIL
Upon FDA clearance of the IND, AUR 200 will be studied in a.